Gottlieb: If Trials Show 'More Certain Benefit,' Risk Can Be Considered Long-Term
US FDA Commissioner says that with strong benefit shown, some risks can be discharged postmarket.
You may also be interested in...
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
‘Better informed patients,’ ‘drug competition,’ ‘biosimilar innovation’ – as well as nutrition and tobacco goals will be achieved through guidances, promotional plans and other items FDA will develop over the next year.
'Patient Experience Data' Section Added To US FDA Drug Reviews
Genentech's hemophilia A treatment Hemlibra is among first products to include new dedicated section on patient experience data in its review documents as FDA begins implementing 21st Century Cures Act provision.
'Progressive Approval' Coming? US FDA Considers Accelerated Approval Without Surrogates
Commissioner Gottlieb tells Congress that concept could be used for some clinical endpoints when a large benefit is seen in a small trial, which could benefit rare disease drug development.